SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results and outlook are driving attention, with traders focused on rapid AI-compute growth, a return to profitability and plans for heavy infrastructure spending. Bulls see the results as evidence of an expanding AI business, while skeptics question the valuation, cash demands and potential share-unlock pressure; preliminary Tesla merger discussions add another speculative theme.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings beat was overshadowed by softer Q4 guidance, slowing revenue growth and a lower advertising outlook, prompting a sharp selloff. Traders are divided between viewing the drop as an overreaction to an otherwise profitable quarter and worrying that weaker growth, engagement and competition will keep pressuring the stock.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary fiscal Q1 update sharply raised its sales outlook and projected improved gross margins, citing stronger AI-platform demand. Bulls welcomed the upside surprise and speculated about short covering, while skeptics questioned whether the gains and improved margins would hold.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

SpaceXs strong AI-related results and spending outlook, alongside Super Micros sharply higher preliminary sales outlook, have traders debating whether Nvidias AI infrastructure demand remains robust. Bulls see the updates as evidence of sustained GPU demand, while skeptics question the debt, power needs, and eventual returns behind the buildout.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS shares sharp rebound has traders focused on the anticipated 80th-event trigger and final analysis of its Phase 3 REGAL AML trial, with some also speculating about a buyout. The event count and trial results remain unconfirmed; bullish expectations of a major catalyst are countered by skepticism that the move is trading momentum without new data.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys upcoming Q3 earnings are the main focus, with traders debating whether results and guidance can justify its premium valuation after a sharp, volatile pullback. Bulls point to fuel-cell demand from AI data centers and recent power-project deals, while skeptics warn that expectations are high and the broader AI selloff could keep shares under pressure.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Traders are focused on potential DefenCath reimbursement upside after the HHS kidney-care plan highlighted barriers to financing dialysis innovation, which they see as support for CorMedixs request for a separate infection-prevention payment category. CMS action remains uncertain, and the discussion also weighs DefenCaths adoption and pricing against competition; REZZAYOs FDA priority review is another cited growth catalyst.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is drawing attention amid a prolonged semiconductor selloff, with traders questioning whether AI infrastructure spending and chip demand can justify the sectors high expectations amid financing concerns and competition. The community is split between expecting an oversold bounce on still-strong AI demand and warning that the decline could deepen.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla and SpaceX have formed independent committees to explore a potential merger, fueling speculation that a combination could benefit Tesla while prompting skepticism about deal terms, valuation, and whether it will happen at all. Traders are also positioning around Teslas upcoming earnings, with debate over whether results or merger-related commentary will drive the next move.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas sharp selloff is being tied to plans for a Monee listing and a new Sea Cloud business, alongside concern about Shopees outlook and spending. Traders disagree on whether the moves could unlock value or add uncertainty, while many point to the stocks technical breakdown and others call it oversold.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLSPR NewswireNEW YORK, Oct. 15, 2026NEW YORK, Oct. 15, 2026 /PRNewswire/ --Pomerantz LLP is...

EvolusExpands Innovation Pipeline with Novel Injectable Hair Restoration Program

Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has entered into an option agreement with a privately held company developing a novel, procedure-based, sustained-release injectable treatment...

EOLS Investors with $100,000 in Losses Have Opportunity to Join Evolus, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Evolus, Inc. (Evolus or the Company) (NASDAQ: EOLS) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on...

UTMD Trades at a Premium to the Industry: How to Play the Stock?

Utah Medical's Orion acquisition, strong cash reserves, improving margins and product expansion efforts support growth prospects and continued shareholder returns.


INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLSPR NewswireNEW YORK, Oct. 8, 2026NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is...

Evolus Warned Over Misbranding in Social Media Promo for Frown Lines Drug

The FDA has warned Evolus that an Instagram post for Jeuveau is false or misleading and misbrands the drug.read more...

FDA Flags Evolus’ Jeuveau Instagram Promotion As Misleading, Seeks Corrective Action

Equity

The FDA objected to claims suggesting Jeuveau could make frown lines gone, deliver complete results, and begin working within two days.

Evolus Launches Wings by Evolus, a New Charitable Platform to Mobilize Its Community in Support of Important Causes

Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the launch of Wings by Evolus, a new charitable platform designed to bring together aesthetic practices, providers, and patients to support...

A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture

A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture PR Newswire NEW YORK, Sept. 1, 2026 NEW...

Wall Street Analysts Think Evolus (EOLS) Could Surge 77.68%: Read This Before Placing a Bet

The mean of analysts' price targets for Evolus (EOLS) points to a 77.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Evolus Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Evolus was asked to respond within 15 working days.</li><li>The FDA sent a letter last year over promotional claims that Jeuveau had advantages over other botulinum toxin products</li><li>FDA approved Jeuveau in 2019 for the temporary improvement of frown lines between the eyebrows in adults.</li></ul><p>Shares of Evolus (EOLS) fell more than 6.5% on Friday to their lowest level in nearly two months after the U.S. Food and Drug Administration (FDA) said an Instagram promotion for the company’s wrinkle treatment Jeuveau was “false or misleading” and created an inaccurate impression of the drug’s benefits and risks.</p><p>The FDA objected to claims suggesting Jeuveau could make frown lines “gone,” deliver “complete results,” and begin working within two days.&nbsp;The agency said the studies primarily measured efficacy at Day 30, while Day 2 findings were exploratory and not strong enough to support such claims.</p><p>The FDA also said the post compared Jeuveau too closely with everyday beauty products while giving its safety risks less prominence. Evolus was asked to respond within 15 working days and explain how it plans to discontinue or correct similar promotional material.</p><h2 class="st-heading-2">What Is Jeuveau?</h2><p>The FDA approved Jeuveau in 2019 for the temporary improvement of moderate-to-severe frown lines between the eyebrows in adults.&nbsp;Like other botulinum toxins, including Botox, the label carries a warning about the possible spread of toxin effects beyond the injection site.</p><p>The latest scrutiny follows a separate FDA letter in September 2025 over promotional claims that Jeuveau’s manufacturing process and formulation gave it advantages over other botulinum toxin products.</p><h2 class="st-heading-2">Evolus’ Broader Portfolio</h2><p>Beyond Jeuveau, Evolus sells Evolysse Form and Smooth, injectable fillers approved in the U.S. The company is awaiting FDA action on Evolysse Sculpt, with approval expected in the fourth quarter (Q4) of 2026.</p><p>Evolus has also licensed Profhilo, a skin-quality injectable which is already used outside the U.S.; commercialization in the U.S. is expected in 2030.</p><h2 class="st-heading-2">Retail’s Take On EOLS</h2><p>Retail sentiment surrounding <a href="https://stocktwits.com/symbol/EOLS">EOLS</a> on Stocktwits turned ‘neutral’ from ‘bearish’ over the past 24 hours.</p><p>The stock has gained around 8% so far this year.&nbsp; &nbsp;&nbsp;</p><p><strong>Also read: </strong><a href="https://stocktwits.com/news-articles/markets/equity/crude-dips-below-100-trump-says-europe-agreed-to-release-massive-amount-of-diesel/cZDjKy2RBKh"><strong>Crude Dips Below $100, Trump Says Europe Agreed To Release ‘Massive Amount’ Of Diesel</strong></a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com</p>

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$7.37
Prev Close	$7.36
Open	$7.38
Dividend Yield	0.00%
50-Day Moving Average	$8.11
Beta	1.12
Avg. Volume	722,939.98
PE Ratio	-13.98

52-Week High	$9.31
52-Week Low	$3.86
Market Capitalization	$486.13M
EPS (Annual)	-$0.801
Price to Book	-15.74
Revenue Per Employee	$889,748.50

Feed

News

Sentiment

Earnings

Fundamentals

Info

EOLS Fundamentals